Real-World Evidence Confirms Tafasitamab Benefit in R/R DLBCL

For patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who are ineligible for autologous stem-cell transplantation, treatment options have historically been limited and outcomes poor. The accelerated approval of tafasitamab-cxix (Monjuvi), a humanized Fc-modified CD19-targeting monoclonal antibody, in combination with lenalidomide (Revlimid) in 2020 introduced a meaningful new option—supported by the single-arm phase 2 L-MIND trial (NCT02399085), which demonstrated a 60% overall response rate (ORR) in a predominantly academic and largely White patient population.

Yet a central question has persisted: how does this regimen perform in the patients and practice settings that define real-world oncology?

Saverno and colleagues now provide a compelling answer. In a retrospective, physician-abstracted chart review of 181 US patients treated with tafasitamab across community and academic settings, they deliver one of the most diverse and practice-representative real-world datasets to date.¹ Their findings not only confirm the effectiveness of tafasitamab/lenalidomide outside the clinical trial setting—but also identify earlier-line use as the single most modifiable determinant of improved outcomes.

A Cohort That Reflects Real-World DLBCL

The study, conducted through the Cardinal Health Oncology Provider Extended Network (OPEN), draws from 23 oncologists—83% practicing in community settings. The resulting cohort differs meaningfully from typical trial populations.

Median age at tafasitamab initiation was 71.1 years. Notably, 22% of patients were Black or African American and 17% were Hispanic or Latino—substantially more representative than the L-MIND trial, in which only 11% of patients were non-White.^1,2

Disease burden was high: 93% had Ann Arbor stage III to IV disease, 80% had R-IPI scores of 3–5, and nearly half (47.5%) had ECOG performance status ≥ 2 at treatment initiation. Twelve percent had double- or triple-hit disease, and 26% had primary refractory DLBCL.

Importantly, 72% received tafasitamab in the second-line (2L) setting, with the remainder treated in later lines.¹

This is not a curated clinical trial population—it is a cohort defined by age, comorbidity, and aggressive disease biology. In other words, it reflects the patients clinicians actually treat.

Robust Responses in a High-Risk Population

Despite this high-risk profile, outcomes were notable.

The real-world ORR reached 73.5% (95% CI, 67.0–79.9%), exceeding the 60% ORR reported in L-MIND.1,2 Complete responses (CR) occurred in 23.2% of patients, with partial responses (PR) in an additional 50.3%.¹

Depth of response translated into durability. Median duration of response was 19.2 months among patients achieving CR versus 8.5 months among those with PR, reinforcing the clinical importance of achieving complete remission.¹

Median real-world progression-free survival (rwPFS) was 11.3 months, and median real-world overall survival (rwOS) was 24.8 months—figures broadly aligned with long-term L-MIND outcomes.^1,3

The higher ORR relative to L-MIND likely reflects differences in patient selection, earlier-line use, and real-world response assessment variability. As the authors note, physician-directed imaging and heterogeneous criteria introduce a degree of variability not present in centrally reviewed trials.¹

Even with these caveats, the signal is clear: tafasitamab/lenalidomide retains—and may even exceed—its efficacy in real-world practice.

The Line-of-Therapy Signal: A Modifiable Determinant of Outcome

Among all findings, the most clinically actionable is the impact of treatment timing.

In multivariable analysis, use of tafasitamab in the third line or beyond (3L–5L) was associated with significantly worse outcomes compared with 2L use. The risk of progression increased by 79% (HR, 1.79; p = 0.004), and the risk of death more than doubled (HR, 2.39; p < 0.001).¹

This aligns closely with long-term L-MIND data demonstrating superior outcomes with earlier-line therapy.³

Taken together, these findings shift the clinical framing of tafasitamab. This is not a salvage therapy reserved for late-stage disease—it is a front-of-mind option at first relapse, particularly for patients unlikely to proceed to transplant or CAR T-cell therapy.

Delaying its use may mean forfeiting the window of maximal benefit.

Performance Status, Disease Burden, and Timing of Intervention

The study further identifies three independent predictors of inferior outcomes:

• ECOG performance status ≥ 2 (HR for death, 3.57; p < 0.001)
• Bulky disease (HR for death, 2.22; p = 0.005)
• Increasing Charlson Comorbidity Index

These factors collectively reinforce a central clinical principle: timing matters.

Patients derive the greatest benefit when tafasitamab is initiated before functional decline, before disease bulk accumulates, and before comorbidity burden escalates. Waiting until patients are clinically deteriorated may substantially diminish therapeutic impact.

Diversity and the Real-World Evidence Gap

An important strength of this study is its representation of racial and ethnic diversity.

Clinical trials in DLBCL have historically underrepresented minority populations. L-MIND enrolled 89% White patients, and other real-world academic datasets report similar distributions.^1,4,5

In contrast, this cohort includes 22% Black and 17% Hispanic patients. The robust ORR observed across this population provides important reassurance regarding the generalizability of tafasitamab/lenalidomide.

While not powered to detect subgroup differences, the study helps close a longstanding gap between trial populations and real-world demographics.

CD19 Sequencing in a Crowded Landscape

The emergence of multiple CD19-directed therapies raises an increasingly relevant question: how should these agents be sequenced?

In this study, 5% of patients received CAR T-cell therapy following tafasitamab.¹ While small, this subgroup reflects a growing real-world scenario.

Prior CD19-directed therapy may theoretically impact subsequent CD19-targeted approaches through antigen modulation. Emerging data suggest that CAR T responses remain achievable but may be attenuated in this context.⁶

Optimal sequencing strategies remain undefined and represent a critical area for prospective study as the therapeutic landscape continues to expand.

Limitations

As a retrospective chart review, the study carries inherent limitations.

Response assessments were not standardized, and variability in imaging and criteria likely influenced reported outcomes. Data abstraction by a limited number of physicians and lack of source verification introduce additional uncertainty. Industry sponsorship should also be considered in interpretation, although the observational design and transparency mitigate some concerns.¹

Despite these limitations, the consistency of findings with prior clinical trial data strengthens the validity of the conclusions.

Implications for Practice

This study reinforces several key points for clinical practice:

• Tafasitamab/lenalidomide is effective in real-world, high-risk, and diverse populations
• Earlier-line use—particularly in the second-line setting—is associated with significantly improved outcomes
• Patient selection and timing are critical, with diminished benefit in patients with poor performance status or advanced disease burden

In an evolving DLBCL landscape that includes bispecific antibodies, novel CD20 and CD19 agents, and CAR T-cell therapies, real-world evidence will be essential to guide sequencing and optimize outcomes.

Bottom Line

Saverno et al. demonstrate that tafasitamab/lenalidomide delivers meaningful clinical benefit across a diverse, community-based R/R DLBCL population—and that earlier use represents the most actionable lever to improve survival.

The implication is straightforward but important: tafasitamab should be considered early, not late, in the treatment course of transplant-ineligible patients.

References

1. Saverno K, Nastoupil LJ, Feinberg B, et al. A Real-World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States. eJHaem. 2026;7:e70256. doi:10.1002/jha2.70256
2. Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978-988. doi:10.1016/S1470-2045(20)30225-4
3. Duell J, Abrisqueta P, Andre M, et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study. Haematologica. 2024;109(2):553-566. doi:10.3324/haematol.2023.283480
4. Lee S, Seeger JD. Racial disparities in DLBCL: analysis of SEER data from 2010–2019. J Clin Oncol. 2023;41(S16):e18552. doi:10.1200/JCO.2023.41.16_suppl.e18552
5. Qualls DA, Lambert N, Caimi PF, et al. Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study. Blood. 2023;142(26):2327-2331. doi:10.1182/blood.2023021274
6. Lownik J, Boiarsky J, Birhiray R, Merchant A, Mead M. Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma. Clin Cancer Res. 2024;30(14):2895-2904. doi:10.1158/1078-0432.CCR-23-1962